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Integrative analysis of breast cancer reveals
prognostic haematopoietic activity and
patient-speciﬁc immune response proﬁles
Frederick S. Varn1, Erik H. Andrews1, David W. Mullins2,3 & Chao Cheng1,3,4

Transcriptional programmes active in haematopoietic cells enable a variety of functions
including dedifferentiation, innate immunity and adaptive immunity. Understanding how
these programmes function in the context of cancer can provide valuable insights into host
immune response, cancer severity and potential therapy response. Here we present a method
that uses the transcriptomes of over 200 murine haematopoietic cells, to infer the
lineage-speciﬁc haematopoietic activity present in human breast tumours. Correlating this
activity with patient survival and tumour purity reveals that the transcriptional programmes
of many cell types inﬂuence patient prognosis and are found in environments of high
lymphocytic inﬁltration. Collectively, these results allow for a detailed and personalized
assessment of the patient immune response to a tumour. When combined with routinely
collected patient biopsy genomic data, this method can enable a richer understanding of the
complex interplay between the host immune system and cancer.
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olid tumours are highly heterogeneous and are made up of
cancer cells and a variety of haematopoietic cells that
comprise the tumour’s microenvironment1. Understanding
how these cell subsets co-evolve in situ can allow for improved
characterization of patient tumours, while providing valuable
information with regard to prognostic prediction and therapeutic
response. Gene expression proﬁling has traditionally been used to
understand the role of neoplastic gene expression programmes in
tumour growth and progression. However, gene expression
activity in tumour-associated haematopoietic cells can alter the
neoplastic gene expression proﬁle, making it possible to infer a
tumour’s cellular composition. In recent times, many methods
have taken advantage of these alterations to computationally
estimate immune activity in biopsies from solid tumours2–5.
These approaches have yielded interesting results, inferring the
presence of haematopoietic subpopulations in several cancers
using the tumour’s expression of lineage-deﬁning signature genes.
However, inﬁltrating haematopoietic cells affect the composite
tumour expression proﬁle transcriptomically, providing
additional information that is not captured by signature-based
methods. Accounting for this information can improve the
sensitivity of these analyses, leading to a more accurate portrayal
of the tumour microenvironment.
The Immunological Genome Project is a joint effort between
immunologists and computational biologists to transcriptomically
proﬁle the murine immune system using carefully controlled
methods of sample collection and data analysis6. To date, over 200
haematopoietic lineages have been proﬁled, making this one of
the most comprehensive gene expression data sets related to
haematopoiesis. The high conservation between murine and
human immune proﬁles makes this data set a rich resource for
probing human haematopoietic subpopulations found in patient
tumours7. Here we use this data set to compare the relative activity
of different haematopoietic expression programmes between
patient tumours. Using breast cancer as our model, we
demonstrate that activity from several lineages correlates with
patient survival, and that many of these programmes are associated
with the presence of inﬁltrating haematopoietic cells. We provide
functional context to our results by investigating each lineage’s
association with immune-related gene expression and analysing
the role of each haematopoietic lineage across breast cancer
subtypes. In addition, we validate our method by applying it to
additional cancer data sets and comparing our results obtained
using murine haematopoietic proﬁles with those from human
proﬁles. Together, these results allow us to sensitively characterize
the haematopoietic activity of the tumour microenvironment and
predict both anticipated and unanticipated cell combinations that
are prognostically signiﬁcant for patient care.
Results
Survival analysis of haematopoietic activity in breast cancer. A
schematic of our analysis is shown in Supplementary Fig. 1. The
BASE algorithm8 was implemented to quantify the rank similarity
between a breast cancer patient’s gene expression proﬁle and each
of the 230 murine haematopoietic lineage proﬁles from the
Immunological Genome Project6. When iteratively applied to the
1,992 patients from the METABRIC data set by Curtis et al.9, this
resulted in a 1,992  230 matrix of rank-similarity metrics, hereby
referred to as Cell Lineage Scores (CLSs). Each patient’s CLS
indicates the relative activity of a cell type compared with that of
other patients. As such, CLSs are useful in distinguishing differing
haematopoietic activity between patients. Each lineage’s CLSs were
used as continuous variables in a univariate Cox proportional
hazards (PH) model, to identify haematopoietic lineages that were
prognostically signiﬁcant (Supplementary Data 1). We evaluated
2

the sensitivity of this analysis by replacing the haematopoietic
proﬁles in our workﬂow with a randomized haematopoietic
data set that was generated by permuting each gene’s expression
levels across haematopoietic cell types. The resulting CLSs from the
permuted data were not signiﬁcantly correlated with patient
survival.
Haematopoietic lineages are diverse, consisting of stem cells,
innate and adaptive immune cells and stromal cells. To account for
these differences in function, the haematopoietic lineages were
grouped into three categories: dedifferentiated, innate and
adaptive. The dedifferentiated category included stem cells and
developmental B cells found in the bone marrow and fetal liver, as
well as developmental T cells found in the thymus. The innate
category included cells involved in innate immunity, speciﬁcally
dendritic cells (DC), macrophages, CD11b þ myeloid cells,
monocytes, natural killer (NK) cells and plasmacytoid DCs
(pDC). Finally, the adaptive category encompassed the cells
involved in adaptive immunity including B cells, CD4 þ
memory/naive T cells, CD8 þ effector/memory/naive T cells, gd
T cells, natural killer T (NKT) cells, regulatory T cells and T-helper
(Th) cells.
CLSs from 75% of the dedifferentiated proﬁles were associated
with poor survival (hazard ratio (HR)41, adjusted Po0.05;
Fig. 1a). This effect is demonstrated in patients dichotomized into
high and low CLS groups for the multi-lineage progenitor derived
from fetal liver and the Fr.D pre-B cell (Fig. 1b). CLSs for 39% of
the innate proﬁles were signiﬁcantly associated with good
prognosis (HRo1, adjusted Po0.05; Fig. 1c). Speciﬁcally, high
CLSs for pDCs, NKs and macrophages were indicators of good
survival, whereas associations for DCs, CD11b þ myeloid cells and
monocytes were mixed. This relationship can be further examined
in the survival distributions for samples dichotomized by CLS for
DAP10  splenic NK cells and CD8  pDCs (Fig. 1d). Survival
association with adaptive immune CLSs was cell-type dependent.
Protective lineages included a variety of B cells, CD4 þ naive
T cells and CD8 þ memory T cells, whereas the deleterious
lineages were primarily CD8 þ effector T cells (Fig. 1e). The
opposing survival distributions for samples dichotomized by CLS
for example CD8 þ memory and effector T cells are shown in
Fig. 1f. Overall, the results from the univariate Cox PH model were
comparable to those using multiple Cox PH regression adjusting
for common clinical variables including age at diagnosis, stage,
oestrogen receptor status, HER2 status and progesterone receptor
status (Supplementary Data 2). Taken together, these results depict
human breast tumours as highly heterogeneous, with numerous
haematopoietic cell-related programmes seemingly involved in
patient survival.
We compared our results obtained using full haematopoietic
expression proﬁles with those obtained using minimal gene sets we
deﬁned to represent each lineage (Supplementary Data 3 and
Methods). Of the 132 lineages whose full expression proﬁles were
signiﬁcantly associated with patient survival in the univariate
analysis, 63 had signiﬁcantly prognostic gene sets (Supplementary
Data 4). These lineages were primarily developmental B cells,
developmental T cells, stem cells, CD8 þ effector T cells and NK
cells. This result suggested that certain lineages survival contribution could be recapitulated using a small number of genes;
however, the low overall number of consistent gene sets underscored the importance of using the entire gene expression proﬁle
when identifying survival-associated haematopoietic programmes.
Associations with tumour purity. Tumour biopsies typically
comprise a variety of cell types from the tumour microenvironment,
including stromal and inﬁltrating immune cells, in addition to
the tumour cells. To stratify inﬁltrate-related transcriptional
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Figure 1 | Haematopoietic lineage survival associations. (a) Distribution of the HRs and adjusted P-values (Wald’s test) derived from univariate Cox PH
models that included dedifferentiated murine haematopoietic cell type CLSs as the variables. Dedifferentiated cell types include developmental B and T cells
(Dev B and Dev T, respectively), and stem cells. Each point corresponds to a different lineage and each colour represents a different haematopoietic
subtype. Cell types above the dotted line are associated with survival at an adjusted P-value o0.05. (b) Kaplan–Meier plot depicting the survival probability
over time for samples with high (red) and low (blue) CLSs for two example dedifferentiated cell types, the multi-lineage progenitor from fetal liver and Fr.D
pre-B cell. (c) Volcano plot displaying univariate Cox PH model results using innate immune lineage CLSs as variables. Innate immune cell subtypes consist
of CD11b þ myeloid (CD11b my), DC, macrophages (Mac), monocytes (Mon), NK and pDC. (d) Kaplan–Meier plot depicting survival probability over time
for two example innate immune cell types, the DAP10  splenic NK cells and CD8  pDCs. (e) Volcano plot displaying results from univariate
Cox PH models that used adaptive immune lineage CLSs as variables. Adaptive immune cell subtypes include B, CD4 þ memory T (CD4 mem), CD4 þ
naive T (CD4 nve), CD8 þ effector T (CD8 eff), CD8 þ memory T (CD8 mem), CD8 þ naive T (CD8 nve), gd T, NKT, regulatory T (T-reg) and Th cells.
(f) Kaplan–Meier plot depicting the survival probability over time for an example CD8 þ memory T cell and CD8 þ effector T cell. For all Kaplan–Meier
plots, samples were stratiﬁed into high and low groups based on whether their CLS was above or below the modal frequency of the CLS distribution for the
given cell type. P-values were calculated using the log-rank test. Vertical hash marks indicate censored data.

programmes from tumour-related ones, we correlated patient CLSs
for each lineage with tumour purity scores calculated using the
ESTIMATE algorithm2 (Fig. 2a). Brieﬂy, ESTIMATE uses singlesample gene set enrichment analysis of a stromal and immune
signature to generate scores that represent the presence of these cell
types in tumour tissue. ESTIMATE then combines these scores to
infer tumour purity. The resulting correlations revealed that CLSs
from dedifferentiated cell types such as the multi-lineage progenitor
and Fr.D pre-B cell were strongly associated with tumour purity

(R ¼ 0.54 and 0.70, respectively), suggesting that dedifferentiated
programmes are intrinsic to the tumour itself (Fig. 2b). Contrarily,
adaptive and innate immune CLSs tended to be negatively
associated with tumour purity, indicating that these CLSs are
capturing immune inﬁltrate-related gene expression. To highlight,
two cell types from the innate category, DAP10  splenic NK cells
and CD8  pDCs, had Pearson’s correlation coefﬁcients of  0.62
and  0.11, respectively, whereas two example adaptive lineages,
CD8 þ memory and effector T cells, had coefﬁcients of  0.35 and

NATURE COMMUNICATIONS | 7:10248 | DOI: 10.1038/ncomms10248 | www.nature.com/naturecommunications

3

ARTICLE

NATURE COMMUNICATIONS | DOI: 10.1038/ncomms10248

a

Purity vs CLS by lineage

R

0.5

0.0

8m

em
(6
DC )
(18
)
Mo
n(
CD
8)
8e
ff (
15
)
NK
T(
4)
Ma
c(
9)
pD
C(
CD
4)
4m
em
(4)
T-r
eg
(5)
B(
1
CD
3)
8n
ve
(5)
γδ
T(
16
)
Str
(10
De
)
vB
(13
CD
)
4n
ve
(
5
De
vT )
(33
)
Ste
m
(14
)
Th
(3)

)
(12

NK

CD

CD

11

bm

y(
33

)

−0.5

Lineage type

b

Dedifferentiated
MLP.FL

Innate
NK.DAP10neg.SP

Adaptive
T.8MEM.SP.OT1.D45.LISOVA

20

20

10
CLS

0

CLS

CLS

10
0

−20

−10
−10

R = 0.54

0.2

0.4

0.6 0.8
Purity

R = −0.62

0.2

PREB.FRD.BM

0

5

R = 0.70

0.2

0.4

0.6 0.8
Purity

0.2

0.4

0.6 0.8
Purity

T.8EFF.SP.OT1.D6.VSVOVA
10

0
−5

−20

R = −0.35

0.6 0.8
Purity

CLS

10

−10

0.4

DC.PDC.8neg.SP

10

CLS

CLS

0

0
−10

−10

R = −0.11

0.2

0.4

0.6 0.8
Purity

−20

R = −0.28

0.2

0.4

0.6 0.8
Purity

Figure 2 | Correlations between haematopoietic lineage CLS and ESTIMATE purity score. (a) Box plot depicting each haematopoietic subtype’s
distribution of Pearson’s correlation coefﬁcients for purity–CLS correlations. Cell subtypes include CD11b þ myeloid (CD11b my), NK, CD8 þ memory T
(CD8 mem), DC, monocytes (Mon), CD8 þ effector T (CD8 eff), NKT, macrophages (Mac), pDC, CD4 þ memory T (CD4 mem), regulatory T (T-reg),
B, CD8 þ naive T (CD8 nve), gd T, stromal (Str), developmental B (Dev B), CD4 þ naive T (CD4 nve), developmental T (Dev T), stem and Th cells. The
numbers in parentheses indicate the number of cells of each lineage type in the Immunological Genome Project data set. Each box spans quartiles with the
lines representing the median correlation coefﬁcient for each group. Whiskers represent absolute range excluding outiers. All outliers were included in the
plot. (b) Scatterplots representing the association between ESTIMATE tumour purity score and CLS for two cell types each from the dedifferentiated, innate
and adaptive haematopoietic categories.

 0.28, respectively (Fig. 2b). Interestingly, CLSs from CD4 þ
naive and Th cells had purity correlations consistent
with dedifferentiated expression programmes. However, a
whole-genome expression correlation between these cell types and
dedifferentiated cell types revealed that CD4 þ naive and Th cells
were transcriptionally similar to the developmental T cells
(Supplementary Data 5). Thus, these correlations were probably a
function of tumour-related gene expression programmes the CLS
was capturing.
As the ESTIMATE algorithm calculates purity scores using the
same gene expression information used to determine the CLS, we
validated our purity correlations using an orthogonal measure of
tumour purity that inferred lymphocytic inﬁltration (LI) based on
image analysis of stained tissue slides10. This method had
previously been applied to the METABRIC data set to calculate
4

LI scores for 564 samples. We used these scores to stratify samples
about the median into high and low LI groups and then examined
the difference between each group’s CLSs for each lymphocytic
lineage (Supplementary Fig. 2). Our analysis revealed that the
LI-high group had signiﬁcantly higher CLSs in 60 of the 88
lymphocytic lineages we tested (Po0.05, two-sided t-test),
suggesting that lymphocytic CLSs are primarily capturing gene
expression programmes associated with inﬁltrating immune cells.
Spatiotemporal patterns of haematopoietic activity.
Understanding the spatiotemporal arrangements of immune
activity can provide insights into how the immune system and
tumour coevolve. We investigated this relationship by examining
the distribution of each lineage’s CLSs across stromal and
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epithelial cells derived from normal, ductal carcinoma in situ
(DCIS) and invasive ductal carcinoma (IDC) tissue using a data
set generated by Ma et al.11 Hierarchical clustering on the basis of
CLS revealed distinct clustering patterns, with DCIS and IDC
epithelial samples clustering apart from stromal samples and
normal epithelial samples (Fig. 3a). CLSs from poor survival
lineages, primarily from the dedifferentiated subset, tended to be
higher in DCIS and IDC epithelial samples, whereas protective
lineages, including most innate and adaptive immune cells, had
higher CLSs in stromal samples (sidebar, Fig. 3a). Interestingly,
CLS clustering revealed few differences between DCIS and IDC
samples, suggesting that dedifferentiation and immune activity
play minimal roles in initiating tumour invasion. Similarly,
clustering of normal, DCIS and IDC stromal samples revealed few
distinct CLS patterns, indicating that high immune activity is a
trait of stromal tissue, regardless of neoplastic status. The CLS
distributions for select lineages can be seen in more detail in
Fig. 3b. Together, these results indicate that tumour immune
activity is highest in the stromal region, whereas tumour epithelial
cells tend to exhibit dedifferentiation programmes. Although
several groups have associated inﬁltrating immune cells with an
invasive phenotype in cancer12, our data suggest that immune
activity in the stromal compartment is not sufﬁcient to induce an

a

invasive programme and, by extension, that qualitative
differences in immune response or multivariate factors in
addition to immune activity may be required to mediate invasion.
Immunological associations with genetic markers. The presence
of inﬁltrating CD8 þ effector T cells at a tumour has traditionally
been associated with good prognosis in a variety of cancer
types13–17. However, our survival analyses indicated that
increased CD8 þ effector T-cell activity was associated with
poor patient survival. We hypothesized that this may be a
function of cancer severity, with higher CD8 þ effector T-cell
activity found at more severe tumours, in apparent contradiction
with the prevailing impression of the ﬁeld18. To test this
hypothesis, we used The Cancer Genome Atlas (TCGA) breast
cancer data to examine the relationship between the total number
of mutations in a sample and its CLSs for each lineage.
Correlation analyses revealed that stem cells and CD8 þ
effector T cells were the cell types most strongly associated with
mutational burden, with Pearson’s correlation coefﬁcients from
both cell types being signiﬁcantly higher relative to background
(P ¼ 4e  3 and 1e  3, respectively, Wilcoxon rank-sum test;
Fig. 4a). The stem cell relationship was not surprising, as high
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Figure 3 | Spatiotemporal arrangement of haematopoietic lineages. (a) Heatmap depicting the hierarchical clustering of CLSs for each haematopoietic
cell type in epithelial and stromal tissue from normal (N, n ¼ 14; NST, n ¼ 14), DCIS (n ¼ 9; DST, n ¼ 11) and invasive ductal carcinoma (IDC, n ¼ 9; IST,
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mutational load and dedifferentiation transcription programmes
are both markers of severe cancer19–21. However, the similar
relationship in CD8 þ effector T cells was interesting, as it
suggested these cells had greater enrichment in severe tumours
relative to other immune lineages.
We followed up this analysis by examining the relationship
between the CLSs from each lineage and CTLA-4 expression
in the Curtis data set. CTLA-4 is a cell surface protein
primarily expressed in T cells that binds B7 molecules with
high afﬁnity, resulting in T-cell inhibition22–24. In the tumour
microenvironment, this can limit T-cell activation and
function. When the lineages were ranked by their Pearson’s
correlation coefﬁcients, CD8 þ effector T cells, CD4 þ
memory cells and CD8 þ memory cells were signiﬁcantly
enriched at the top of the rankings relative to other lineages
(P ¼ 6e  8, 5e  3 and 2e  3, respectively, Wilcoxon rank-sum
test). Interestingly, B7-expressing macrophage cells were
signiﬁcantly enriched at the bottom of the rankings (P ¼ 1e  4,
Wilcoxon rank-sum test; Fig. 4b), indicating a decrease in CTLA4 levels and perhaps T-cell abundance in their presence. Together,
these results suggest that high immunosuppressive activity may
be limiting T-cell effector functions in the tumour
microenvironment.

a

Tumour necrosis factor-related apoptosis inducing ligand
(TRAIL, CD253) is a cytokine known to induce apoptosis in
tumour cells and has commonly been used as a target in
anticancer therapies25,26. Various cells of the innate immune
system are known to express TRAIL27. To investigate the
relationship between immune inﬁltrate and TRAIL expression,
we ranked each lineage based on its Pearson’s correlation
coefﬁcient between CLS and TRAIL expression (Fig. 4c).
Interestingly, we found that pDCs and NK cells were
signiﬁcantly enriched at the top of these rankings (P ¼ 6e  4
and 9e  4, respectively, Wilcoxon rank-sum test), suggesting that
these cells may mediate TRAIL expression as part of their
protective effect.
Patterns of activity across breast cancer subtypes. Breast cancer
subtyping is useful for characterizing breast cancer samples and
predicting prognosis. The METABRIC data set included sample
information for both prediction analysis of microarray 50
(PAM50) subtypes28,29 and the integrative clustering subtypes by
Curtis et al.9 We hypothesized that these subtypes may reﬂect
varying haematopoietic activity encapsulated by each sample’s set
of CLSs. To examine this association, we ﬁrst stratiﬁed samples by
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Figure 4 | CLS correlations with mutational burden and gene expression. The ﬁgure represents ranked Pearson’s correlation coefﬁcients describing the
association between a sample’s CLS for a given cell type and their (a) total number of mutations, (b) CTLA-4 expression and (c) TRAIL expression. In all
ﬁgures, each bar represents a different cell type, with red and green bars representing positive and negative correlations, respectively. Below each ﬁgure,
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macrophages (Mac), pDCs and NK cells.
6

NATURE COMMUNICATIONS | 7:10248 | DOI: 10.1038/ncomms10248 | www.nature.com/naturecommunications

ARTICLE

NATURE COMMUNICATIONS | DOI: 10.1038/ncomms10248

HR
CLS

HR>1
Basal

HER2

Luminal A

−20 −10 0 10 20

Luminal B

Nrm

HR<1
P>0.05

A

B

C

D

Figure 5 | Haematopoietic lineage association with PAM50 subtypes. Heatmap depicting the hierarchical clustering of CLSs for each haematopoietic cell
type in basal (n ¼ 331), HER2 (n ¼ 240), luminal A (n ¼ 721), luminal B (n ¼ 492) and normal-like (Nrm) (n ¼ 202) tumours (column sidebar). To show
contrast, the max and min CLS were set to the 99th percentile of the original CLS distribution. Left row sidebar depicts the four distinct CLS clusters (A–D)
that emerged. Right row sidebar represents the HRs for each haematopoietic cell type based on the univariate Cox PH survival analysis done in the Curtis
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their PAM50 subtype and hierarchically clustered the lineages by
CLS across the Curtis data set. Interestingly, this method revealed
that four major clusters of 33, 59, 90 and 48 lineages, labelled
A–D, respectively, had distinct activity in the individual PAM50
subtypes (Fig. 5). Repeating this method using the Curtis et al.
subtypes revealed a similar pattern (Supplementary Fig. 3).
These four clusters had unique compositions of cell types linked
by their prognostic associations, each with distinct activity in the
individual subtypes. Cluster A was enriched in adaptive immune
cells (P ¼ 3.2e  6, Fisher’s exact test) with varying survival
associations. The deleterious cell types in this cluster exhibited
high activity in the basal-like, HER2 and luminal B subtypes,
whereas the protective lineages did not display clear subtypespeciﬁc patterns. Cluster B was enriched in dedifferentiated cell
types (P ¼ 3.9e  25, Fisher’s exact test). These lineages tended to
be associated with poor survival and had their highest activity in
the basal-like, HER2 and luminal B subtypes. Cluster C was
characterized by an abundance of innate immune cell types
(P ¼ 4.3e  14, Fisher’s exact test). In addition to innate cell types,
this cluster also included all the stromal cell types and some
adaptive immune cell types. These cell types were primarily
associated with good survival and had their highest scores in the
luminal A and normal-like subtypes. Finally, cluster D was
enriched in haematopoietic lineages with no prognostic
association (P ¼ 1.8e  9, Fisher’s exact test). The activity of
cells in this cluster showed no distinct patterns across the
subtypes. These results indicated that although subtypes are
deﬁned by distinct clinical characteristics, they sometimes share
similar haematopoietic features.
These relationships were further demonstrated by examining
the distribution of PAM50 subtypes after clustering samples by
their CLSs (Supplementary Fig. 4). This analysis yielded
four distinct clusters of samples, deﬁned by a mixture of either

basal-like, HER2 and luminal B subtypes or luminal A and
normal-like subtypes. Interestingly, each cluster exhibited a
signiﬁcantly different survival distribution from the others
(P ¼ 3e  6, log-rank test). Taken together, these ﬁndings suggest
that although the PAM50 subtyping system is capturing the
molecular underpinnings of a patient’s disease, a novel subtyping
system may better reﬂect the haematopoietic activity present in a
patient’s tumour.
The differences in haematopoietic activity across subtypes led
us to stratify samples by both PAM50 and Curtis et al. subtype,
and re-examine the association between survival and CLS for
each haematopoietic lineage (Supplementary Data 6 and 7). Many
of these survival associations were no longer signiﬁcant after
stratiﬁcation, indicating that subtyping captured much of the
haematopoietic diversity within breast cancer samples. However,
some lineages remained prognostic in certain subtypes. To
demonstrate this ﬁnding in more detail, we performed example
two class comparisons for lineages that remained signiﬁcantly
predictive of patient survival in individual PAM50 and Curtis
et al. subtypes (Supplementary Figs 5 and 6).
Reproducibility of haematopoietic survival analyses. To
conﬁrm that our ﬁndings were not localized to the Curtis data set,
we extended our univariate survival analysis to four additional
breast cancer data sets by Ur-Rehman et al.30, Wang et al.31,
van de Vijver et al.32 and Schmidt et al.33 At an adjusted P-value
of 0.05, 131 lineages were signiﬁcantly predictive of survival in at
least 3 data sets and 69 were signiﬁcantly predictive across all
5 data sets tested (Supplementary Data 8). These results indicate
that the CLSs from a large number of haematopoietic lineages are
reproducible measurements of patient survival in breast cancer.
Figure 6 shows the survival distributions of samples from each
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Figure 6 | Reproducibility of T8.MEM.SP.OT1.D45.LISOVA CLS survival association in breast cancer data sets. Kaplan–Meier plots depicting the
survival probability over time for samples with a high (red) and low (blue) CLS for the T8.MEM.SP.OT1.D45.LISOVA cell type, an example CD8 þ memory
T cell. Samples were stratiﬁed into high and low groups based on whether their CLS was above or below the modal frequency of the CLS distribution for the
given cell type. P-values were calculated using the log-rank test. Vertical hash marks indicate censored data.

data set stratiﬁed by CLSs from an example CD8 þ memory
T-cell lineage. This lineage was signiﬁcantly associated with
patient survival in all ﬁve data sets tested.
Survival analyses across multiple tumour types. The strong and
robust survival associations our framework identiﬁed in breast
cancer encouraged us to apply our framework to other tumour
types. CLSs were calculated for samples in prostate cancer34,
non-small cell lung cancer (NSCLC)35 and TCGA skin cutaneous
melanoma (SKCM) data sets and ﬁtted to univariate Cox PH
models (Supplementary Data 9–11, respectively). The results
from these survival analyses suggested a cancer-speciﬁc role for
different immune lineages in patient survival. For instance, in
prostate cancer, high CD8 þ effector T-cell CLSs were indicative
of a poor prognosis and NK cell CLSs were not signiﬁcantly
associated with patient survival (Fig. 7a). In NSCLC, high DC
CLSs were associated with poor prognosis, whereas CD8 þ
effector T-cell CLSs were not signiﬁcantly associated with patient
survival (Fig. 7b). Finally, in SKCM, high CD8 þ effector T-cell
CLSs and NK-cell CLSs were both associated with prolonged
survival (Fig. 7c). Together, these results demonstrate that our
method can be applied to numerous cancers and may be a
valuable tool going forward in dissecting the role of the immune
system in various tumour types.
Recapitulation of results using human proﬁles. The associations
we identiﬁed in this study were determined by assuming that
CLSs calculated from murine haematopoietic proﬁles were
representative of analogous underlying human cell populations.
To validate this assumption, we used the BASE algorithm to
calculate CLSs in two human haematopoietic data sets by Abbas
et al.36 and Novershtern et al.37 (Supplementary Data 12 and 13).
After renormalizing the resulting CLSs across human lineages,
this analysis enabled us to globally identify the human
8

haematopoietic lineages that most strongly correspond with the
murine lineages. In both data sets, CLSs from the murine lineages
were primarily highest in their analogous human lineages,
indicating high cell-type similarity between species.
As a follow-up to this analysis, we calculated CLSs in the
METABRIC data set using the human haematopoietic gene
expression proﬁles in lieu of the murine proﬁles. We then ﬁt
the resulting CLSs to a univariate Cox PH model and compared the
results we obtained using murine proﬁles with those from each
human data set. Surprisingly, only the human immune lineages in
the Abbas et al. data set were signiﬁcantly correlated with patient
survival. To check for consistency between the Abbas et al. results
and the results we obtained using the murine proﬁles, we correlated
the human gene expression proﬁles with each murine gene
expression proﬁle, to identify the murine lineage that was most
similar to each human lineage. We then compared the survival
results between each human proﬁle and its best matched murine
proﬁle (Supplementary Data 14). Our analysis demonstrated that
each human lineage was most strongly correlated with an
analogous murine lineage. In addition, for each human–murine
lineage pair where both lineages were signiﬁcantly predictive of
patient survival (adjusted Po0.01, Wald’s test), the HRs of each
lineage indicated a consistent protective or deleterious effect on
survival.
Discussion
We have developed an integrated approach to computationally
identify active haematopoietic transcriptional programmes in a
patient’s tumour sample based on transcriptional similarity to
murine haematopoietic proﬁles. By using continuous transcriptional
proﬁles from 230 haematopoietic cell lineages, our approach
provides high sensitivity in classifying which haematopoietic
expression programmes are most prominent in patient tumours.
Correlation analyses between CLS and tumour purity indicate that
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Figure 7 | Example CLS survival distributions in three additional cancer types. (a) Kaplan–Meier plots depicting the survival probability over time for
prostate cancer samples with high (red) and low (blue) CLSs for an example CD8 þ effector T cell and activated NK cell. (b) Kaplan–Meier plot depicting
the survival probability over time in non-small cell lung carcinoma (NSCLC) patients with high and low CLSs for CD103 þ CD11b  DCs and an example
CD8 þ effector T cell. (c) Kaplan–Meier plot depicting the survival probability over time in SKCM patients with high and low CLSs for an example CD8 þ
effector T cell and ly49 þ NK cells. For all Kaplan–Meier plots, samples were stratiﬁed into high and low groups based on whether their CLS was above or
below the modal frequency of the CLS distribution for the given cell type. P-values were calculated using the log-rank test. Vertical hash marks indicate
censored data.

these haematopoietic programmes are likely to be associated with
inﬁltrating immune cells in the patient tumour microenvironment
or dedifferentiated transcriptional programmes intrinsic to the
tumour itself. This systematic approach can be used for a variety of
basic science and clinical applications.
Gene expression analyses provide only a snapshot in time of
the overall struggle between cancer and the immune system.
Keeping this in mind, the presence of cells at a tumour site may
simply serve as prognostic biomarkers, even if they are not
directly involved in antitumour response. Our survival analyses
revealed that the activity of pDCs, NK cells, macrophages, B cells,
CD4 þ naive cells and CD8 þ memory T cells was associated
with enhanced survival. Some of these lineages including pDCs
and NK cells are well characterized for their antitumour
effects38,39. However, others such as B cells, CD4 þ naive cells
and CD8 þ memory cells are typically found at the site of a
previous successful immune response33,40–42. This complicates
our understanding of why inﬁltrate of each lineage is associated
with a survival response. However, quantiﬁcation of lineage
activity at the tumour site using this method remains valuable for
prognostic purposes and these results can be used to generate
novel hypotheses for future investigation in preclinical and
patient-centred trials. If validated, these observations could
change our understanding of cancer immunology and inform
future immunotherapy approaches.
Surprisingly, we found that the primary immune-related
indicator of poor prognosis was the presence of CD8 þ effector
T cells in the tumour microenvironment. These ﬁndings run
contrary to many previous reports13–17. Our attempts to provide
functional context to this result revealed that CD8 þ effector

T-cell activity was strongly associated with mutational burden
and the expression of the immunosuppressive protein CTLA-4.
This analysis suggested that the presence of CD8 þ effector
T cells in a tumour might be an indicator of immunoevasive
breast cancer. We suspect, based on our results, that CD8 þ
effector T cells arrive early in the breast tumour development.
Once there, they successfully elicit an antitumour response,
leading to the presence of CD8 þ memory T cells and
other protective-associated lineages. However, if the tumour
has become immunoevasive, such as by inducing
immunosuppression through CTLA-4, inﬁltrating CD8 þ
effector cells will be ineffective. As the tumour continues to
mature, more CD8 þ effectors will be recruited to the tumour to
little effect, leading to the negative association between CD8 þ
effector CLS and patient survival. Alternatively, these data could
suggest that classic CD8 þ effectors are of less importance than a
speciﬁc subset of CD8 þ memory cells, which in the current
analysis cannot be distinguished. For example, recent evidence
supports prognostic and therapeutic efﬁcacy of CD103 þ tissueresident CD8 þ memory cells in ovarian and lung cancer43,44.
Although we believe many of the protective lineages found in
the tumour are indicative of a previous successful immune
response, we observed that NK cells and pDCs correlated well
with the expression of the antitumour protein TRAIL. TRAIL is
constitutively expressed in NK cells but cells that express
interferon-a/b such as pDCs, monocytes and other NK cells
have been shown to further induce its expression38,39,45.
We suspect that the presence of pDCs in a tumour induces
TRAIL expression in NK cells, leading to increased apoptosis
in tumour cells, thus conferring a survival-protective effect.
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Further exploration of this relationship may reveal important
details in regards to breast cancer immunotherapy and
immunosurveillance.
When applied to three additional cancer types, our method
suggested that the role of the immune system on patient survival
is strikingly context dependent. Some of these associations
have been previously reported. For instance, prostate tumours
have been shown to escape NK immunosurveillance by shedding
the NK cell-activating ligand NKG2D46, which is in agreement
with our ﬁnding that NK cells are not signiﬁcantly associated with
patient survival. In addition, our results relating to the differing
roles of CD8 þ effector T cells in melanoma and NSCLC patients
agree with previous reports that CD8 þ effector T cells have a
protective role in melanoma patients and no association with
survival in NSCLC patients47,48. However, other associations we
found had not been well characterized, such as the negative
association between DCs and NSCLC patient survival.
Understanding the different avenues by which the immune
system inﬂuences patient survival across cancer types will have
important implications regarding immunotherapy in the future.
The systematic manner by which our approach associates
haematopoietic programmes with patient survival should enable
more detailed analyses going forward.
Our approach employs a user-selected haematopoietic gene
expression data set to query the cell-speciﬁc programmes active in
a patient’s tumour. This data set should be carefully chosen to
ensure that the resulting associations faithfully represent the
underlying biology. Taking this into consideration, we established
the use of murine haematopoietic proﬁles as proxies for measuring
human haematopoietic subpopulations. Murine proﬁles offer
several advantages over human proﬁles, as mice can be easily
manipulated to allow for comprehensive genomic proﬁling and
diminished variability between experiments. By using this resource,
we were able to detect activity for several haematopoietic lineages
whose role in cancer had not been extensively characterized.
However, many of the cell types in this data set were highly
correlated, diminishing the speciﬁcity of our analysis. Going
forward, this method could be improved through employing a data
set that better contrasts related cell types. Alternatively, the BASE
algorithm could be modiﬁed to place greater weight on the genes
that best deﬁne each individual cell type. By applying these
changes, a more thorough depiction of the tumour haematopoietic
landscape can be obtained.
As demonstrated, using our approach to examine associations
between immune activity, patient survival and cytogenetic
features can generate numerous hypotheses. Experimental
validation of these prospective models will be critical in further
understanding the interplay between the immune system and
cancer. Going forward, this method can be implemented in
consort with sequencing data, to identify potential immunogenic
mutations that may alter the cellular makeup of the tumour
microenvironment. In addition, as our preliminary results in
multiple tumour types demonstrate, this method can be applied
in a pan-cancer manner to compare the immune system’s role in
different disease contexts. The high sensitivity of this method
enables multiple follow-up analyses with the potential to provide
important insights into tumour immunology. By combining these
insights with mechanistic experimentation, the immune system’s
role in cancer management can be further elucidated.

Pre-processing of haematopoietic proﬁles. To calculate the CLS using the BASE
algorithm8, haematopoietic gene expression proﬁles must ﬁrst be transformed so
that each value reﬂects the gene’s relative expression level in a given cell type.
Beginning with a haematopoietic data set (GSE15907, GSE22886 or GSE24759),
relative gene expression values are obtained by median normalizing the absolute
expression values across cell types. From there, each cell type’s relative gene
expression values are z-transformed so that they follow a standard normal
distribution. At this point, z-scores 40 mark genes that are upregulated in a given
cell type relative to other cells in this data set, whereas z-scores o0 mark the genes
that are downregulated in a given cell type relative to the other cells. If necessary,
replicate gene expression proﬁles for each cell type are collapsed at this step by
taking the mean z-score of each replicate. Each newly collapsed cell type’s z-scores
are then z-transformed again to renormalize. From there, each cell type’s z-score
proﬁle is split into an up- and downregulated proﬁle. In the upregulated proﬁle,
genes with a z-score 40 maintain their value while genes with a z-score o0 are
converted to 0, whereas the downregulated proﬁle maintains the z-scores o0,
converting z-scores 40 to 0. By splitting the proﬁles into up- and downregulated
proﬁles, z-scores can now be converted into P-values without losing information
regarding the relative expression of a gene in each cell type. The P-values are then
 log10 transformed, to add more weight to genes that exhibit higher differential
expression. To avoid outliers, transformed values 410 are then trimmed to 10.
Finally, the transformed values are divided by the maximum value in the data set,
to rescale values from 0 to 1.
To create a random data set to test the sensitivity of our method, each gene’s
expression values from GSE15907 were shufﬂed between haematopoietic lineages
to create novel cell proﬁles. This shufﬂed data was then subjected to the preprocessing steps described above. To create minimal gene sets for each lineage in
GSE15907, the pre-processed haematopoietic upregulated proﬁles were ﬁltered to
only include genes whose values were equal to 1, indicating strong differential
expression, in at least one lineage. This resulted in a simpliﬁed matrix containing
each lineage’s upregulated proﬁle values in 997 genes (Supplementary Data 3).
Each lineage had a transformed value of 1 in at least 5 of the 997 genes included in
the matrix.
Calculation of the CLS. The BASE algorithm calculates the CLS by applying the
transformed haematopoietic proﬁles/gene sets to patient gene expression data. The
up- and downregulated proﬁles for each haematopoietic cell type are treated as a
weight vector w ¼ [w1, w2, w3ywjywn], where wj ¼  log10(p-val) for gene j in
that cell lineage and n ¼ number of genes. Each patient’s gene expression values are
log transformed and median normalized across samples, to reﬂect each sample’s
relative expression level. The relative expression levels are then ordered from high
to low and deﬁned as the vector g ¼ [g1, g2, g3ygjygn], where gj ¼ the relative
expression value of gene j in a given patient and n ¼ number of genes. BASE then
inputs these two vectors into a foreground and background function, which are
used to calculate a ‘pre-CLS’ for the upregulated (pCLSup) and downregulated
(pCLSdn) proﬁles:
The foreground function calculates the cumulative distribution of the patient
gene expression values weighted by their corresponding transformed hematopoietic
expression values:

Pi 

j¼1 gj wj 
f ðiÞ ¼ Pn 
;1  i  n
gj w j 

ð1Þ

j¼1

The background function calculates the cumulative distribution of the patient gene
expression values weighted by a value complementary (1  w) to their
corresponding transformed haematopoietic expression values:

Pi  

j¼1 gj 1  wj 
 ;1  i  n
bðiÞ ¼ Pn  
gj 1  wj 

ð2Þ

j¼1

Methods
Gene expression and clinical data. Gene expression and associated clinical data
sets were obtained from the European Genome-Phenome Archive
(EGAS00000000083), the Gene Expression Omnibus (GSE15907, GSE22886,
GSE24759, GSE14548, GSE47561, GSE2034, GSE11121, GSE16560 and GSE8894)
and from the website of the Netherlands Cancer Institute (http://ccb.nki.nl/data/).
10

In addition, BRCA and SKCM level 3 gene expression data from the RNAseqV2
platform and the associated clinical data were obtained from the TCGA data portal
(http://cancergenome.nih.gov/). Raw gene expression data from the Immunological
Genome Project (GSE15907), obtained in July 2014, was background corrected
using Robust Microarray Analysis, quantile normalized and ﬁtted with a multichip
linear model for each probeset using the ‘expresso’ function of the ‘affy’ library in
R49. Probes from the Affymetrix MoGene-1_0-st, HG-U133A, HT_HG-U133A,
U133_X3P, HG-U133Plus2.0 and Illumina 6k Transcriptionally Informative Gene
Panel for DASL platforms were collapsed into gene symbols using the probe with
the highest average intensity across all samples. Murine transcripts from the
Affymetrix MoGene-1_0-st platform were matched to human transcripts using
gene symbol.

The pCLSup and pCLSdn are then each calculated by taking the maximum absolute
deviation between their respective foreground and background functions. The
maximum deviation could be the maximum difference when the foreground
function is larger than the background function (pCLS þ ) or the minimum
difference when the background function is larger than the foreground function
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(pCLS  ). As a result, these two differences must be compared:
þ
¼ max½f ðimax Þ  bðimax Þ; 0; where imax
pCLSup=dn

¼ argmaxi¼1;2;3 ... n ½f ðiÞ  bðiÞ

ð3Þ

dichotomized about the median LI score into LI-low and LI-high groups.
Lymphocytic lineages in the Immunological Genome Project were deﬁned as all
non-developmental B cells, T cells and NK cells. For each lymphocytic lineage, the
mean CLS from the LI-high group was compared with that from the LI-low group
using a two-sided t-test.


pCLSup=dn
¼ min½f ðimin Þ  bðimin Þ; 0; where imin

¼ argmini¼1;2;3 ... n ½f ðiÞ  bðiÞ
pCLSup=dn ¼

n

pCLS þ ;pCLS þ 4jpCLS  j
pCLS  ;otherwise

ð4Þ
ð5Þ

The resulting statistic provides information regarding the similarity between a
patient gene expression proﬁle and the up/downregulated haematopoietic proﬁle.
For patients whose gene expression proﬁles closely match an upregulated
haematopoietic cell proﬁle the foreground cumulative distribution function will
sharply increase early, as highly expressed patient genes in vector g are assigned
high corresponding haematopoietic weights from vector w, before plateauing later
due to lowly expressed patient genes being assigned low weights. The background
cumulative distribution function will behave conversely, with highly expressed
genes assigned low complementary weights and lowly expressed genes assigned
high complementary weights. When the maximum deviation between the two
functions is calculated, the resulting pCLSup will be high, corresponding to the high
similarity between the patient and haematopoietic expression proﬁles. For patient
proﬁles that are compared with concordant downregulated haematopoietic proﬁles,
high weights will correspond to lowly expressed haematopoietic genes. As a result,
the roles of the foreground and background cumulative distribution functions will
be swapped relative to the upregulated function and the high similarity will result
in a highly negative pCLSdn. For patient expression proﬁles that are compared with
highly discordant haematopoietic proﬁles, both the foreground and background
functions are expected to increase randomly, as the haematopoietic weights will not
correspond to high or low expression values. This will result in a low maximum
deviation between the two cumulative distribution functions and a low pCLSup/dn.
To normalize the pCLSup and pCLSdn, the gene labels in vector g are permuted
1,000 times to obtain 1,000 permuted gene expression vectors g1, g2,y, g1,000. For
each permutation, a pCLSup/dn is then recalculated by replacing g in equations (1)
and (2) with the respective permuted expression vector. This procedure results in
1,000 pCLS variables that are used to generate a null pCLS distribution. The pCLSup
and pCLSdn are then normalized by dividing each score by the mean of the absolute
value of the permuted pCLS variables to yield the CLSup and CLSdn. The ﬁnal CLS is
then obtained by subtracting the CLSdn from the CLSup.
Survival analyses. Survival-associated haematopoietic lineages were identiﬁed
using a univariate Cox PH model ﬁtted to a given lineage’s CLSs across all breast
cancer samples. To correct for potential confounders of the univariate analysis in
the Curtis et al. data set, we performed multiple Cox PH regression, incorporating
the CLS, as well as age at diagnosis, stage, oestrogen receptor status, HER2 status
and progesterone receptor status. Signiﬁcance of the model parameters was
determined using Wald’s test and the resulting P-values were adjusted using the
Benjamini–Hochberg procedure. Survival distributions were visualized using
Kaplan–Meier curves, with samples dichotomized into high- and low-risk groups
about the modal frequency of their CLS distribution. Signiﬁcance of the difference
between the survival distributions was assessed using a log-rank test.
Survival analyses were performed in R using the ‘coxph’, ‘survﬁt’ and ‘survdiff’
functions of the ‘survival’ package for Cox PH models, Kaplan–Meier plots and
log-rank tests, respectively.
Haematopoietic lineage grouping. GSE15907, which originally contained 237
haematopoietic lineages, was ﬁltered to remove seven cell types that were either
control samples or ambiguously named (CD4posTESTNA, CD4posTESTDB,
CD4TESTJS, CD4TESTCJ, CD19CONTROL, CD4CONTROL and AG). The
remaining 230 lineages were assigned a group and subgroup based on the type of
haematopoietic cell they represented. The developmental B-cell group was
deﬁned as all early-phase B cells found in the fetal liver and bone marrow. The
developmental T-cell group was deﬁned as all thymal ab T cells and immature
thymal gd T cells. All CD11b þ myeloid cells were assigned to the CD11b þ
myeloid cell category, regardless of myeloid subtype. The remaining subgroups
were assigned based on characterization done by the Immunological Genome
Project (http://www.immgen.org/)6.
Tumour purity estimation. Gene expression-based tumour purity was estimated
in R using the ‘estimate’ package2. For a given data set, the ‘ﬁlterCommonGenes’
function was used to select for the genes used by the ESTIMATE algorithm.
The ‘estimateScore’ function then used the expression levels of these genes to
calculate an ESTIMATE score for each sample. From there, these scores were
inputted into the previously calculated tumour purity formula to infer a sample’s
purity. ESTIMATE-based tumour purity values were correlated with CLSs for each
haematopoietic lineage using the ‘cor’ function in R. LI scores calculated from
eosin-stained tissue sections of 564 METABRIC samples were downloaded from
the website of the Yinyin Yuan laboratory (http://www.yuanlab.org/). Samples were

Mutation count in TCGA data. Breast cancer (BRCA) level 3 somatic mutation
data were accessed for breast cancer patients from the TCGA data portal
(http://cancergenome.nih.gov/). Mutation count was calculated by summing all
mutations that did not fall under the ‘silent’ and ‘RNA’ variant classiﬁcation
categories in the TCGA BRCA somatic mutation calling data. CLSs for each lineage
were then calculated for each TCGA breast cancer sample and correlated with each
sample’s mutation count using the ‘cor’ function in R. Lineages were then ranked
by their Pearson’s correlation coefﬁcients. Relative enrichment at the top or bottom
of the rankings for a given lineage subtype was calculated using a Wilcoxon
rank-sum test that compared CLSs for lineages of that subtype with CLSs from
lineages not of that subtype (background).
Gene expression correlations. Gene expression levels for the CTLA-4 and TRAIL
proteins were derived from the Curtis et al. data set under the gene symbols
‘CTLA4’ and ‘TNFSF10’, respectively. Expression values for each gene were
correlated with CLSs for each haematopoietic lineage using the ‘cor’ function in
R. Lineages were then ranked based on their Pearson’s correlation coefﬁcients.
Relative enrichment at the top or bottom of the rankings was calculated using the
same procedure as for mutation count.
Code availability. The R code for the BASE algorithm can be found in
Supplementary Software 1.
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